Analysts Set TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Target Price at $11.79

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has earned an average rating of “Buy” from the nine analysts that are presently covering the company, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $11.79.

Several equities analysts have issued reports on the company. Oppenheimer started coverage on TriSalus Life Sciences in a research note on Monday, September 16th. They issued an “outperform” rating and a $10.00 price target on the stock. Roth Mkm began coverage on shares of TriSalus Life Sciences in a research report on Monday, November 11th. They set a “buy” rating and a $11.00 target price on the stock. Northland Securities assumed coverage on shares of TriSalus Life Sciences in a research note on Friday, October 25th. They set an “outperform” rating and a $12.50 target price on the stock. Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Finally, Northland Capmk raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th.

TriSalus Life Sciences Stock Performance

Shares of NASDAQ:TLSI opened at $5.16 on Thursday. The company has a market capitalization of $157.34 million, a PE ratio of -2.07 and a beta of 0.51. The company’s fifty day moving average is $4.36 and its 200-day moving average is $4.80. TriSalus Life Sciences has a 52 week low of $3.50 and a 52 week high of $10.42.

Insider Buying and Selling

In related news, major shareholder Equity Ab Frankenius purchased 62,972 shares of the firm’s stock in a transaction that occurred on Tuesday, December 17th. The stock was acquired at an average price of $3.97 per share, for a total transaction of $249,998.84. Following the completion of the acquisition, the insider now owns 6,230,748 shares of the company’s stock, valued at $24,736,069.56. This represents a 1.02 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have acquired 70,012 shares of company stock worth $281,235 in the last quarter. Insiders own 32.80% of the company’s stock.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of hedge funds have recently bought and sold shares of TLSI. Highbridge Capital Management LLC purchased a new stake in shares of TriSalus Life Sciences during the second quarter valued at approximately $1,184,000. Duquesne Family Office LLC grew its stake in TriSalus Life Sciences by 35.1% in the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after purchasing an additional 110,966 shares during the period. Walleye Capital LLC purchased a new stake in shares of TriSalus Life Sciences during the 3rd quarter valued at $66,000. MSD Partners L.P. bought a new stake in shares of TriSalus Life Sciences during the 3rd quarter worth $184,000. Finally, Vestcor Inc purchased a new position in shares of TriSalus Life Sciences in the 3rd quarter worth about $108,000. 2.58% of the stock is owned by hedge funds and other institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.